(₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
---|---|---|---|---|---|
Total Income | 5821.42 | 5715.02 | 5226.78 | 1.9% | 11.4% |
Total Expenses | 4750.15 | 4660.16 | 4490.68 | 1.9% | 5.8% |
Profit Before Tax | 1071.27 | 1054.86 | 736.10 | 1.6% | 45.5% |
Tax | 212.41 | 195.38 | 117.40 | 8.7% | 80.9% |
Profit After Tax | 858.86 | 859.48 | 618.70 | -0.1% | 38.8% |
Earnings Per Share | 18.70 | 18.60 | 13.40 | 0.5% | 39.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Lupin Ltd is a leading pharmaceutical company, primarily engaged in the manufacture and distribution of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company operates in the highly competitive pharmaceutical industry, known for its focus on research and development to introduce cost-effective and innovative healthcare solutions. Recent developments for Lupin Ltd include strategic expansions, new product launches, and initiatives to enhance global reach, although specific details related to such developments are not available in the provided data.
For the quarter ending Q3FY25, Lupin Ltd reported a total income of ₹5821.42 crores, reflecting a 1.9% increase from the previous quarter (Q2FY25) where the total income stood at ₹5715.02 crores. Compared to the same quarter in the previous year (Q3FY24), the total income showed an 11.4% increase from ₹5226.78 crores. This growth suggests a positive trend in the company's revenue generation over both quarterly and yearly comparisons.
Lupin Ltd's profitability metrics for Q3FY25 exhibit stability and growth. The company reported a profit before tax of ₹1071.27 crores, marking a 1.6% increase from Q2FY25's ₹1054.86 crores and a significant 45.5% rise from Q3FY24's ₹736.10 crores. The tax expense in Q3FY25 was ₹212.41 crores, an 8.7% increase from the previous quarter and an 80.9% increase year-over-year. The profit after tax for Q3FY25 was ₹858.86 crores, slightly decreasing by 0.1% from Q2FY25 but showing a substantial 38.8% increase compared to Q3FY24. Earnings per share in Q3FY25 were ₹18.70, reflecting a 0.5% increase quarter-over-quarter and a 39.6% increase year-over-year.
Operating expenses for Lupin Ltd in Q3FY25 amounted to ₹4750.15 crores, showing a 1.9% increase from ₹4660.16 crores in Q2FY25 and a 5.8% increase from ₹4490.68 crores in Q3FY24. These figures indicate consistent growth in the company's operational outlay over the periods considered. The operating metrics suggest that while expenses have risen, the growth in total income and profitability has kept pace, maintaining the company's operational efficiency.